GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aligos Therapeutics Inc (NAS:ALGS) » Definitions » Equity-to-Asset

Aligos Therapeutics (Aligos Therapeutics) Equity-to-Asset : 0.47 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aligos Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aligos Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $59.80 Mil. Aligos Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $127.90 Mil. Therefore, Aligos Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.47.

The historical rank and industry rank for Aligos Therapeutics's Equity-to-Asset or its related term are showing as below:

ALGS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.48   Med: 0.72   Max: 0.83
Current: 0.47

During the past 6 years, the highest Equity to Asset Ratio of Aligos Therapeutics was 0.83. The lowest was -1.48. And the median was 0.72.

ALGS's Equity-to-Asset is ranked worse than
66.52% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ALGS: 0.47

Aligos Therapeutics Equity-to-Asset Historical Data

The historical data trend for Aligos Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aligos Therapeutics Equity-to-Asset Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -0.44 0.83 0.79 0.71 0.61

Aligos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.66 0.64 0.61 0.47

Competitive Comparison of Aligos Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Aligos Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aligos Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's Equity-to-Asset falls into.



Aligos Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Aligos Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=92.08/151.527
=0.61

Aligos Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=59.796/127.902
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aligos Therapeutics  (NAS:ALGS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Aligos Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Aligos Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aligos Therapeutics (Aligos Therapeutics) Business Description

Traded in Other Exchanges
Address
One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Executives
Roche Finance Ltd 10 percent owner C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Matthew W. Mcclure officer: Chief Medical Officer C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Surplus Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Julian A. Symons officer: See Remarks C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Leonid Beigelman director, officer: President C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lucinda Y. Quan officer: See Remarks C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lawrence Blatt director, officer: Chief Executive Officer

Aligos Therapeutics (Aligos Therapeutics) Headlines

From GuruFocus